NORTHWEST BIOTHERAPEUTICS INC (NWBO)

↓ Download CSV

CIK 0001072379 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, NORTHWEST BIOTHERAPEUTICS INC reported revenue of $1.38M, down 0.3% from the prior year. The company ran a net loss, with a net margin of -4365.9%. It held $81.29M in total assets against $128.86M in total liabilities.

Key ratios (FY2025)

-4347.9%
Operating margin
-4365.9%
Net margin
-0.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$1.38M$1.38M$1.93M
Operating Income-$59.91M-$66.51M-$55.51M-$67.18M-$52.70M-$86.61M-$27.98M-$41.48M-$54.68M-$79.27M
Net Income-$60.16M-$83.78M-$62.60M-$105.03M$179.13M-$529.82M-$20.81M-$35.79M-$73.14M-$80.21M
EPS (Diluted)$-0.04$-0.07$-0.06$-0.10$0.21$-0.73$-0.04
Total Assets$81.29M$26.73M$27.86M$31.32M$40.16M$32.90M$10.64M$24.67M$48.91M$52.91M
Total Liabilities$128.86M$105.71M$74.92M$136.37M$164.15M$395.85M$55.70M$71.83M$96.20M$79.41M
Shareholders' Equity-$60.28M-$94.49M-$65.77M-$128.10M-$123.99M-$362.95M-$45.05M-$48.13M-$67.33M-$26.50M
Cash & Equivalents$3.04M$2.17M$2.13M$6.96M$15.17M$9.98M$372.0K$22.22M$117.0K$6.87M
Operating Cash Flow-$44.76M-$57.02M-$53.64M-$52.77M-$38.30M-$32.09M-$31.86M-$34.59M-$36.49M-$55.65M
Capital Expenditures$1.50M$1.01M$171.0K
Shares Outstanding1.56B1.33B1.18B1.07B948.40M829.60M614.30M523.20M328.90M157.00M